DailyIQ
Last updatedUpdating…

LH·Labcorp Holdings Inc.

$317.53
+3.89 (+1.24%)
High
$319.75
Open
$314.10
Market Cap
25.44B
52W High
$341.80
Low
$314.10
P. Close
$317.53
P/E
25.38
52W Low
$244.52
Fwd P/E
15.81
DailyIQ Est.
$354.02
Inst. Ownership
37.8%
Short Interest
3.31%
Days to Cover
3.0
Div. Yield
0.92%
Next Ex-Div
~Nov 27
Technical Score (1D)
58
BULLISH
News Sentiment
47
MIXED
On Oct 13, Labcorp announced the launch of the Thrive 5 Health Test, its first laboratory offering in partnership with Arianna Huffington’s Thrive Global. The test is available through Labcorp OnDemand and combines Labcorp’s clinical insights with Thrive Global’s behavior‑change technology. The collaboration aims to provide consumers with actionable health information and practical improvement strategies. This development was reported by Labcorp as a new way to deliver health data and behavioral guidance to patients. The partnership highlights Labcorp’s expansion into consumer‑direct health testing and its focus on integrating technology to support health behavior change.
LOW TARGET
$293 -7.7%
2 analysts
MEAN TARGET
$345 +8.7%
14 analysts
HIGH TARGET
$385 +21.3%
13 analysts
PRICE RANGE
$293.00 - $385.00
SB / B / H / S / SS
9/12/6/1/1
DAILYIQ EST.
$354.02 (+11.5%)
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NYQ
Country
United States
Symbol
LH
Description
Labcorp Holdings Inc. is a leading provider of comprehensive laboratory services, operating through two primary segments: Diagnostics Laboratories and Biopharma Laboratory Services. The company's core business involves a wide array of diagnostic testing, ranging from routine blood and urine analyses to specialized tests for complex conditions like cancer, infectious diseases, and genetic disorders. Labcorp also offers essential services to the biopharmaceutical industry, supporting drug development and medical device testing. Serving a diverse clientele that includes healthcare providers, pharmaceutical companies, and managed care organizations, Labcorp facilitates critical healthcare decisions and advances scientific research through its extensive testing capabilities. Its online and mobile platforms provide convenient access to services and results for both patients and healthcare professionals.
Bought (1Y)
0 shares
$0
Sold (1Y)
11,267 shares
$3.5M
Caveney Brian JEVP, Pres of BLS, CMO & CSO
Award/Grant3,000 shares2026-09-01
Vaughn Bryan TEVP and President, Diagnostics
Award/Grant1,500 shares2026-09-01
Meltzer Jonathan CEVP, COO
Award/Grant900 shares2026-09-01
Oyegunwa AkinboladeEVP, CIO & CTO
Award/Grant750 shares2026-09-01
ANDERSON KERRII B-
Sell3,000 shares2026-08-17
68/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
28.8%
Net Margin
6.3%
Revenue CAGR
7.1%
Current Ratio
1.42x
Debt / Equity
0.65x
Return on Equity
10.2%
Earnings Summary
Labcorp Holdings Inc. is a leading provider of comprehensive laboratory services, operating through Diagnostics Laboratories and Biopharma Laboratory Services, serving healthcare providers, pharmaceutical companies, and managed care organizations. The company’s diagnostics and research offerings place it firmly within the broader healthcare diagnostics sector, a space characterized by steady demand for clinical testing and growing specialty testing markets. In the most recent quarters, Labcorp posted a revenue of $3.5355 billion in Q3 2025 and $3.5158 billion in Q4 2025, a slight decline from the $3.5273 billion in Q2 2025, indicating a modest deceleration in top‑line growth. EPS, however, continued to rise, with $4.18 in Q3 2025 versus $4.35 in Q2 2025, and $4.07 in Q4 2025 versus $4.18 in Q3 2025, reflecting a consistent beat of analyst expectations in each of the last four quarters (EPS estimates of $4.13813, $3.94198, $4.2163, and $4.9212 respectively). Historically, Labcorp has maintained a YoY revenue growth trajectory of roughly 5–6% over the past three years, while EPS growth has accelerated from $3.45 in Q4 2024 to $4.99 in Q2 2026, underscoring a pattern of earnings expansion even as revenue growth moderates. Recent news highlights the firm’s expansion into high‑growth specialty testing markets such as oncology and women’s health, coupled with AI and automation initiatives aimed at boosting productivity and margins; these developments align with the company’s resilient performance amid macroeconomic uncertainty.

EPS

EstBeatMiss
$3.78$4.13$4.47$4.81$5.15Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$4.65 - -
Q2'26$4.92$4.99+1.4%
Q1'26$4.22$4.25+0.8%
Q4'25$3.94$4.07+3.2%
Q3'25$4.14$4.18+1.0%
Q2'25$4.18$4.35+4.1%

Revenue

EstBeatMiss
$3.5B$3.6B$3.7B$3.8B$3.9BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.9B - -
Q2'26$3.8B$3.7B-2.4%
Q1'26$3.6B$3.5B-2.0%
Q4'25$3.6B$3.5B-1.2%
Q3'25 - $3.6B -
Q2'25 - $3.5B -

Market Data

LH Stock Snapshot

NEUTRAL58/100
$317.53+$3.89 (1.2%)
Market cap
25.44B
P/E ratio
25.4
Day range
$314.10 – $319.75
News sentiment
47/100 · Neutral
Analyst target
$345.12 (+8.7%)
Consensus
Buy · 29 analysts
52-week range+29.9% off low · -7.1% from high
$244.52$341.80
Price $317.53 DailyIQ Est. $354.02

LH sits in the upper part of its 52-week range with the technical picture unresolved. In Healthcare, names this size usually take direction from sector flows before company-level news.

Reverse DCF

What growth is priced into LH?

FAIR

At today's price, Labcorp Holdings Inc. needs to grow free cash flow about 7.9% a year for the next 10 years to justify its valuation at a 7.55% cost of capital. Over its actual history it has compounded free cash flow at 5.4% a year, so the market is asking for 2.5 percentage points above its own delivered rate. On that basis LH looks priced roughly in line with its own growth record.

Implied FCF growth
7.9%
Historical FCF CAGR
5.4%
Growth gap
+2.5 pts
Verdict
FAIR
Discount rate (WACC)
7.55%
Beta
0.63

Behaviour On Record

What LH's own history says about today's numbers

Realized volatility (21d)
18.2% 42nd pct
Below its peak
-7.7%
vs 200-day average
+11.0%
Up days (1y)
51%

Labcorp Holdings Inc. is currently running 18.2% annualised volatility over the last 21 sessions. Measured against LH's own 13 years of daily returns rather than a market-wide average, that is the 42nd percentile — close to its own typical level, against a typical reading of 19.5%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

LH is trading -7.7% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -17.3%, and the deepest was -46.6% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +11.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 79th percentile — a somewhat wider gap than its own norm. Over the past year LH closed higher on 51% of sessions, and it is currently 2 sessions into a falling streak.

On October specifically: over 14 years of records, LH finished the month higher 10 of 14 times, with a median return of +1.6% and an average of +1.1%. Its strongest month historically has been July at +4.1% on average, its weakest March at -2.8%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: LH has opened more than 2% away from the prior close in 97 of 3,268 sessions (3.0% of the time), with the largest gaps running +27.8% and -7.0%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, LH moved an average of 1.9% in the session after earnings, closing higher 1 of those 3 times, with a median move of -2.0% and a largest of -2.9%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against LH's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of LH's sector?

Labcorp Holdings Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91

Options Market

What is the options market pricing for LH?

CallsPuts

For Labcorp Holdings Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 1.17), with at-the-money implied volatility around 28.4%. The options market is pricing roughly a ±2.7% move by that expiry — a range of about $311.12–$328.08.

Put/call ratio (2026-10-16)
1.17
ATM implied volatility
28.4%
Total open interest
941
Expected move by 2026-10-16
±2.7% ($311.12–$328.08)

Analyst Rating Changes

Are analysts turning bullish or bearish on LH?

Truist Securities most recently reiterated its rating on Labcorp Holdings Inc. to Buy on Sep 21, 2026 with a price target of $365 (from $350). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Truist Securities — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Sep 21, 2026Truist SecuritiesMaintainedBuy$350 → $365
Sep 11, 2026UBSMaintainedBuy$361 → $380
Sep 11, 2026BarclaysMaintainedEqual-Weight$320 → $330
Aug 4, 2026Piper SandlerMaintainedNeutral$300 → $309
Aug 3, 2026JP MorganMaintainedOverweight$330 → $360
Jul 31, 2026Morgan StanleyMaintainedOverweight$308 → $338
Jul 31, 2026Truist SecuritiesMaintainedBuy$320 → $350
Jul 31, 2026BarclaysMaintainedEqual-Weight$290 → $320
Jul 13, 2026B of A SecuritiesMaintainedBuy$300 → $320
Jul 13, 2026BairdMaintainedOutperform$335 → $338
Apr 8, 2026Evercore ISI GroupMaintainedOutperform$280 → $300
Feb 24, 2026Piper SandlerMaintainedNeutral$270 → $300

Peers & ETF holders

LH peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

47/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Labcorp (LH) announced the launch of the Thrive 5 Health Test, its first laboratory offering in partnership with Arianna Huffington’s Thrive Global. The test is available through Labcorp OnDemand and combines Labcorp’s clinical insights with Thrive Global’s behavior‑change technology. The collaboration aims to provide consumers with actionable health information and practical improvement strategies.
What did this article say?
Labcorp Holdings Inc. (LH) generates revenue from routine and specialty medical tests, supporting drug development and personalized treatments. The company’s growth prospects hinge on investments in equipment, technology, and capacity to capture expanding demand from physicians, hospitals, and pharmaceutical firms. Analysts question whether the current earnings discount accurately reflects the long‑term value of these investments, raising concerns about potential undervaluation. The debate highlights the tension between short‑term earnings pressure and long‑term capital expenditures required to sustain growth.
What did this article say?
Labcorp Holdings (LH) is scheduled to release its third‑quarter 2026 earnings later this month. Wall Street analysts anticipate a profit increase at a lower‑double‑digit rate compared to the same period a year earlier. The forecast suggests continued growth momentum for the diagnostics company, reinforcing expectations of solid financial performance.
What did this article say?
Evercore ISI reduced its price target for Labcorp Holdings (LH) from $340 to $330 while keeping an outperform rating. The adjustment reflects a modest downward view of LH’s valuation relative to peers. The firm cited recent earnings and market conditions as reasons for the tighter target. The change is unlikely to trigger a significant shift in investor sentiment but may influence short‑term trading activity. Overall, the move signals a cautious outlook for LH’s near‑term performance.
What did this article say?
Labcorp Holdings Inc. (NYSE: LH) announced that it will release its third‑quarter 2026 financial results on October 28, 2026, prior to the market open. The company will host a 9:00 a.m. ET webcast to discuss the results, with the press release and supporting data posted on its Investor Relations website. A replay of the webcast will be available for one year. The announcement provides a schedule for investors but does not disclose any performance metrics or guidance changes.
What did this article say?
Labcorp Holdings Inc. (LH) announced continued expansion into high‑growth specialty testing markets such as oncology, women’s health, autoimmune disease and neurology, supported by new acquisitions and health‑system contracts. The company is also leveraging artificial intelligence and automation to improve productivity and margins. While macroeconomic uncertainty and reimbursement changes pose potential headwinds, LH’s recent performance—23.4% YTD share price gain versus 4.8% industry growth—indicates resilience. These developments suggest a positive trajectory for the diagnostics firm, though risks remain from external policy shifts.
What did this article say?
Labcorp (LH) shares fell after the CMS released preliminary 2027 lab‑payment rates, which align Medicare rates more closely with private insurers and could cut reimbursements by up to 15%. The analyst argues the market overreacted, citing that the final rates are still pending and the impact on LH’s bottom line is likely limited. Despite the short‑term sell‑off, the company’s fundamentals remain strong, and the current price is viewed as a discount.
What did this article say?
Labcorp Holdings announced at its 2026 Investor Day a strategic focus on targeted acquisitions and investment in advanced lab management systems and digital patient experiences. Management highlighted a plan to deploy capital toward integrating new platforms with its existing diagnostic infrastructure, aiming to streamline operations and data handling. The move signals a shift toward a more technology‑centric model, potentially enhancing competitive positioning in the diagnostics market. The announcement is a positive catalyst for the stock, though the magnitude of upside remains contingent on execution.
What did this article say?
Labcorp Holdings (LH) has delivered strong recent performance, outpacing the Dow by 22.5% over the past three months and 24.2% year‑to‑date. The stock has risen 11.7% over the last year, while the Dow gained only 11.8%. Despite a current 8.9% decline from its 52‑week high, the trend remains bullish with LH trading above both its 50‑day and 200‑day moving averages. The company’s global footprint and expansion into specialty testing and biopharma services underpin its growth trajectory.
What did this article say?
Labcorp (LH) confirmed its 2029 earnings and revenue growth guidance, maintaining an adjusted EPS growth range of 8.5% to 11.5% and revenue growth of 5% to 8%. The company also reiterated a 75 to 150 basis‑point improvement in adjusted operating margin through 2029. In its filing, LH highlighted concerns that CMS fee schedule changes starting in 2027 may not reflect broader market conditions, potentially leading to payment cuts that could affect patient access to lab services.

Technical Analysis

Real-time indicators across multiple timeframes

58
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $8.23B combined position · 13 adding, 12 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy9,850,63112.15%$2.47B2026-01-29
BlackRock, Inc.▲ Buy6,574,2618.11%$1.84B2026-08-07
Geode Capital Management, LLC▲ Buy2,188,8902.70%$610.44M2026-08-12
FMR LLC (Fidelity)▲ Buy1,904,8702.35%$533.36M2026-08-13
Morgan Stanley▲ Buy1,609,4471.98%$450.65M2026-08-13
JPMorgan Chase & Co▼ Sell1,268,3841.56%$354.62M2026-08-12
Invesco Ltd.▼ Sell1,237,6761.53%$346.55M2026-08-14
Northern Trust Corp▼ Sell883,0761.09%$247.26M2026-08-13
Wellington Management Group LLP▼ Sell855,5961.05%$239.57M2026-08-14
Bank of America Corp▲ Buy812,2701.00%$227.44M2026-08-14
Norges Bank▼ Sell810,0931.00%$226.83M2026-08-12
Goldman Sachs Group Inc▲ Buy435,4560.54%$121.93M2026-08-14
AllianceBernstein L.P.▼ Sell418,3850.52%$111.63M2026-08-14
Wells Fargo & Company▲ Buy347,5440.43%$97.31M2026-08-14
Squarepoint Ops LLC▲ Buy258,4380.32%$72.36M2026-08-14
Millennium Management LLC▲ Buy228,0430.28%$63.85M2026-08-14
Point72 Asset Management, L.P.▼ Sell137,4440.17%$38.48M2026-08-14
Janus Henderson Group plc▼ Sell128,8710.16%$34.38M2026-05-18
Citigroup Inc▼ Sell101,8840.13%$28.53M2026-08-03
Marshall Wace, LLP▲ Buy96,6660.12%$27.07M2026-08-13
Gotham Asset Management, LLC▼ Sell90,7220.11%$25.40M2026-08-14
Man Group plc▼ Sell73,6490.09%$20.62M2026-08-14
AQR Capital Management LLC▲ Buy60,9990.08%$16.93M2026-08-14
Prudential Financial Inc▼ Sell44,1810.05%$12.37M2026-08-12
D. E. Shaw & Co., Inc.▲ Buy40,0310.05%$11.21M2026-08-14
Q2 2026 flow:1.34M sh bought ($376.18M)1.46M sh sold ($403.46M)net -119.4K sh (−$27.27M)
Congressional Trading Activity
20 disclosed trades · ~$327.0K est. traded value · 13 buys, 7 sells
MemberChamberStateTypeAmountTradedFiled
April McClain DelaneyHouseMD06▼ Sell$100K - $250K2026-08-252026-09-09
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2026-08-072026-09-09
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2026-08-062026-09-09
April McClain DelaneyHouseMD06▼ Sell$1K - $15K2026-08-052026-09-09
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2026-02-112026-03-10
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2026-02-042026-03-10
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2026-01-282026-02-02
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-11-172025-12-08
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-10-312025-11-04
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-10-292025-11-04
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-05-31
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-05-08
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-03-312025-04-07
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-02-282025-03-20
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-02-272025-03-20
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-02-082025-03-20
April McClain DelaneyHouseMD06▲ Buy$1K - $15K2025-02-052025-03-20
Dan SullivanSenateAK▼ Sell$1K - $15K2023-08-222023-09-22